{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:47:54Z","timestamp":1791686874360,"version":"4.3.4"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008436","name":"National Foundation for Medical Research and Innovation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100008436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5 RO1 CA 001833-02"],"award-info":[{"award-number":["5 RO1 CA 001833-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Breast Cancer Foundation of Australia","award":["CG-12-07"],"award-info":[{"award-number":["CG-12-07"]}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP210103151"],"award-info":[{"award-number":["DP210103151"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1173669"],"award-info":[{"award-number":["APP1173669"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The current endoscopy and biopsy diagnosis of esophageal adenocarcinoma (EAC) and its premalignant condition Barrett\u2019s esophagus (BE) is not cost-effective. To enable EAC screening and patient triaging for endoscopy, we developed a microfluidic lectin immunoassay, the EndoScreen Chip, which allows sensitive multiplex serum biomarker measurements. Here, we report the proof-of-concept deployment for the EAC biomarker Jacalin lectin binding complement C9 (JAC-C9), which we previously discovered and validated by mass spectrometry. A monoclonal C9 antibody (m26 3C9) was generated and validated in microplate ELISA, and then deployed for JAC-C9 measurement on EndoScreen Chip. Cohort evaluation (n = 46) confirmed the expected elevation of serum JAC-C9 in EAC, along with elevated total serum C9 level. Next, we asked if the small panel of serum biomarkers improves detection of EAC in this cohort when used in conjunction with patient risk factors (age, body mass index and heartburn history). Using logistic regression modeling, we found that serum C9 and JAC-C9 significantly improved EAC prediction from AUROC of 0.838 to 0.931, with JAC-C9 strongly predictive of EAC (vs. BE OR = 4.6, 95% CI: 1.6\u201315.6, p = 0.014; vs. Healthy OR = 4.1, 95% CI: 1.2\u201313.7, p = 0.024). This proof-of-concept study confirms the microfluidic EndoScreen Chip technology and supports the potential utility of blood biomarkers in improving triaging for diagnostic endoscopy. Future work will expand the number of markers on EndoScreen Chip from our list of validated EAC biomarkers.<\/jats:p>","DOI":"10.3390\/cancers13122865","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:08:55Z","timestamp":1623154135000},"page":"2865","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Julie A.","family":"Webster","sequence":"first","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-0478","authenticated-orcid":false,"given":"Alain","family":"Wuethrich","sequence":"additional","affiliation":[{"name":"Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik B.","family":"Shanmugasundaram","sequence":"additional","affiliation":[{"name":"Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8911-8966","authenticated-orcid":false,"given":"Renee S.","family":"Richards","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta M.","family":"Zelek","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University, Heath Park, Cardiff CF10 3AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok K.","family":"Shah","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-4249","authenticated-orcid":false,"given":"Louisa G.","family":"Gordon","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Kendall","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Herston, Brisbane, QLD 4102, Australia"},{"name":"Department of Gastroenterolgy and Hepatology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Hartel","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-7676","authenticated-orcid":false,"given":"B. Paul","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University, Heath Park, Cardiff CF10 3AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-1280","authenticated-orcid":false,"given":"Matt","family":"Trau","sequence":"additional","affiliation":[{"name":"Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia"},{"name":"School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-0951","authenticated-orcid":false,"given":"Michelle M.","family":"Hill","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"},{"name":"Faculty of Medicine, The University of Queensland, Herston, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s10620-018-5148-7","article-title":"Screening and Surveillance for Barrett\u2019s Esophagus: Is It Cost-Effective?","volume":"63","author":"Inadomi","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.giec.2020.08.007","article-title":"Advances in Biomarkers for Risk Stratification in Barrett\u2019s Esophagus","volume":"31","author":"Souza","year":"2021","journal-title":"Gastrointest. Endosc. Clin. North Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.giec.2020.08.004","article-title":"Progress in Screening for Barrett\u2019s Esophagus","volume":"31","author":"Tan","year":"2021","journal-title":"Gastrointest. Endosc. Clin. North Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s10620-018-5068-6","article-title":"Barrett\u2019s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?","volume":"63","author":"Thrift","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s10620-019-06018-2","article-title":"Risk Prediction Models for Barrett\u2019s Esophagus Discriminate Well and Are Generalizable in an External Validation Study","volume":"65","author":"Ireland","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ajg.2012.446","article-title":"Prediction of Barrett\u2019s Esophagus Among Men","volume":"108","author":"Rubenstein","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.gastro.2016.09.040","article-title":"Diagnosis and Management of Low-Grade Dysplasia in Barrett\u2019s Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association","volume":"151","author":"Wani","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2589-7500(19)30216-X","article-title":"Development and validation of a risk prediction model to diagnose Barrett\u2019s oesophagus (MARK-BE): A case-control machine learning approach","volume":"2","author":"Rosenfeld","year":"2020","journal-title":"Lancet Digit. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The Epidemiology of Esophageal Adenocarcinoma","volume":"154","author":"Coleman","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.giec.2020.08.001","article-title":"Epidemiology of Barrett\u2019s Esophagus and Esophageal Adenocarcinoma","volume":"31","author":"Cook","year":"2021","journal-title":"Gastrointest. Endosc. Clin. North Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/apt.15760","article-title":"Systematic review with meta-analysis: Prevalence of prior and concurrent Barrett\u2019s oesophagus in oesophageal adenocarcinoma patients","volume":"52","author":"Tan","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1055-9965.EPI-20-0223","article-title":"Barrett\u2019s Esophagus and Esophageal Adenocarcinoma Biomarkers","volume":"29","author":"Grady","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1055-9965.EPI-12-1415","article-title":"Early Diagnostic Biomarkers for Esophageal Adenocarcinoma\u2014The Current State of Play","volume":"22","author":"Shah","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/elps.201100341","article-title":"High-throughput lectin magnetic bead array-coupled tandem mass spectrometry for glycoprotein biomarker discovery","volume":"32","author":"Choi","year":"2011","journal-title":"Electrophoresis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1074\/mcp.M115.050922","article-title":"Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma","volume":"14","author":"Shah","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1074\/mcp.RA118.000734","article-title":"Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett\u2019s Esophagus","volume":"17","author":"Shah","year":"2018","journal-title":"Mol. Cell. Proteom."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, J., Wuethrich, A., Dey, S., Lane, R.E., Sina, A.A.I., Wang, J., Wang, Y., Puttick, S., Koo, K.M., and Trau, M. (2020). The Growing Impact of Micro\/Nanomaterial-Based Systems in Precision Oncology: Translating \u201cMultiomics\u201d Technologies. Adv. Funct. Mater., 30.","DOI":"10.1002\/adfm.201909306"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1021\/acs.chemrev.7b00668","article-title":"Surface-Enhanced Raman Spectroscopy for Bioanalysis: Reliability and Challenges","volume":"118","author":"Zong","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_19","first-page":"1","article-title":"A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1021\/acs.accounts.9b00192","article-title":"Toward Personalized Cancer Treatment: From Diagnostics to Therapy Monitoring in Miniaturized Electrohydrodynamic Systems","volume":"52","author":"Khondakar","year":"2019","journal-title":"Accounts Chem. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nancarrow, D.J., Clouston, A.D., Smithers, B.M., Gotley, D.C., Drew, P.A., Watson, D.I., Tyagi, S., Hayward, N., Whiteman, D.C., and For the Australian Cancer Study and the Study of Digestive Health (2011). Whole Genome Expression Array Profiling Highlights Differences in Mucosal Defense Genes in Barrett\u2019s Esophagus and Esophageal Adenocarcinoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022513"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1158\/1055-9965.EPI-05-0370","article-title":"Interactions among smoking, obesity, and symptoms of acid reflux in Barrett\u2019s esophagus","volume":"14","author":"Smith","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"38876","DOI":"10.18632\/oncotarget.9113","article-title":"A global assessment of the male predominance in esophageal adenocarcinoma","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1038\/ncomms10588","article-title":"Structure of the poly-C9 component of the complement membrane attack complex","volume":"7","author":"Dudkina","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_25","first-page":"495","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nat. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1385\/1-59259-056-X:53","article-title":"Immunoaffinity Methods for Purification of Complement Components and Regulators","volume":"Volume 150","author":"Morgan","year":"2003","journal-title":"Complement Methods and Protocols"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.imbio.2018.07.016","article-title":"Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers","volume":"223","author":"Zelek","year":"2018","journal-title":"Immunobiology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1905614","DOI":"10.1002\/smll.201905614","article-title":"Tracking Drug-Induced Epithelial\u2013Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/physci241020a0","article-title":"Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions","volume":"241","author":"Frens","year":"1973","journal-title":"Nat. Phys. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03725-8","article-title":"Characterising the phenotypic evolution of circulating tumour cells during treatment","volume":"9","author":"Tsao","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1366\/000370207782597003","article-title":"Automated Autofluorescence Background Subtraction Algorithm for Biomedical Raman Spectroscopy","volume":"61","author":"Zhao","year":"2007","journal-title":"Appl. Spectrosc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prevetmed.2017.11.018","article-title":"A discussion of calibration techniques for evaluating binary and categorical predictive models","volume":"149","author":"Fenlon","year":"2018","journal-title":"Prev. Veter-Med."},{"key":"ref_33","unstructured":"The United States Food and Drug Administration (2020, September 01). Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q2-r1-validation-analytical-procedures-text-and-methodology."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A Practical Guide to Immunoassay Method Validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ab.2011.02.013","article-title":"Optimization of the enzyme-linked lectin assay for enhanced glycoprotein and glycoconjugate analysis","volume":"413","author":"Thompson","year":"2011","journal-title":"Anal. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/natrevmats.2016.21","article-title":"Nanostructure-based plasmon-enhanced Raman spectroscopy for surface analysis of materials","volume":"1","author":"Ding","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.14309\/ajg.0000000000000650","article-title":"Overutilization of Endoscopic Surveillance in Barrett\u2019s Esophagus: The Perils of Too Much of a Good Thing","volume":"115","author":"Cotton","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","unstructured":"Australian Commission on Safety and Quality in Health Care (2018). Third Australian Atlas of Healthcare Variation 2018, Australian Commission on Safety and Quality in Health Care."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bios.2015.03.006","article-title":"Portable smartphone quantitation of prostate specific antigen (PSA) in a fluoropolymer microfluidic device","volume":"70","author":"Barbosa","year":"2015","journal-title":"Biosens. Bioelectron."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1746.2010.06506.x","article-title":"Is endoscopic surveillance for non-dysplastic Barrett\u2019s esophagus cost-effective? Review of economic evaluations","volume":"26","author":"Hirst","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00260","DOI":"10.14309\/ctg.0000000000000260","article-title":"Public Preferences and Predicted Uptake for Esophageal Cancer Screening Strategies: A Labeled Discrete Choice Experiment","volume":"11","author":"Peters","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eabb9601","DOI":"10.1126\/science.abb9601","article-title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention","volume":"369","author":"Lennon","year":"2020","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1021\/acs.analchem.6b04527","article-title":"Proteoform Profile Mapping of the Human Serum Complement Component C9 Revealing Unexpected New Features of N-, O-, and C-Glycosylation","volume":"89","author":"Franc","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/pmic.201000127","article-title":"Upregulation of plasma C9 protein in gastric cancer patients","volume":"10","author":"Chong","year":"2010","journal-title":"Proteomics"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Miyauchi, E., Furuta, T., Ohtsuki, S., Tachikawa, M., Uchida, Y., Sabit, H., Obuchi, W., Baba, T., Watanabe, M., and Terasaki, T. (2018). Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193799"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1349-7006.2010.01818.x","article-title":"Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray","volume":"102","author":"Murakoshi","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.jprot.2011.07.019","article-title":"Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC)","volume":"74","author":"Narayanasamy","year":"2011","journal-title":"J. Proteom."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Thurman, J.M., Laskowski, J., and Nemenoff, R.A. (2020). Complement and Cancer\u2014A Dysfunctional Relationship?. Antibodies, 9.","DOI":"10.3390\/antib9040061"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00268-016-3819-0","article-title":"Toward More Efficient Surveillance of Barrett\u2019s Esophagus: Identification and Exclusion of Patients at Low Risk of Cancer","volume":"41","author":"Lindblad","year":"2016","journal-title":"World J. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.gie.2013.07.046","article-title":"Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett\u2019s esophagus","volume":"79","author":"Gordon","year":"2014","journal-title":"Gastrointest. Endosc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2865\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:07Z","timestamp":1760163127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13122865"],"URL":"https:\/\/doi.org\/10.3390\/cancers13122865","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}